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Objective. To estimate and compare the prevalence of ﬁbromyalgia by 2 different methods in Olmsted County, Minne-
sota.
Methods. The ﬁrst method was a retrospective review of medical records of potential cases of ﬁbromyalgia in Olmsted
County using the Rochester Epidemiology Project (from January 1, 2005, to December 31, 2009) to estimate the prevalence
of diagnosed ﬁbromyalgia in clinical practice. The second method was a random survey of adults in Olmsted County
using the ﬁbromyalgia research survey criteria to estimate the percentage of responders who met the ﬁbromyalgia
research survey criteria.
Results. Of the 3,410 potential patients identiﬁed by the ﬁrst method, 1,115 had a ﬁbromyalgia diagnosis documented in
the medical record by a health care provider. The age- and sex-adjusted prevalence of diagnosed ﬁbromyalgia by this
method was 1.1%. By the second method, of the 2,994 people who received the survey by mail, 830 (27.6%) responded and
44 (5.3%) met the ﬁbromyalgia research survey criteria. The age- and sex-adjusted prevalence of ﬁbromyalgia in the
general population of Olmsted County by this method was estimated at 6.4%.
Conclusion. To the best of our knowledge, this is the ﬁrst report of the rate at which ﬁbromyalgia is being diagnosed in
a community. This is also the ﬁrst report of prevalence as assessed by the ﬁbromyalgia research survey criteria. Our
results suggest that patients, particularly men, who meet the ﬁbromyalgia research survey criteria are unlikely to have
been given a diagnosis of ﬁbromyalgia.
INTRODUCTION
Fibromyalgia (FM) is a complex illness to diagnose and
treat, with symptoms that may be part of or overlap with
other diseases or syndromes. It is also a costly public
health problem. Medical costs related to health care utili-
zation and pain-related medications for patients with FM
are substantially higher than those for patients without FM
(1–4). Therefore, evaluating the prevalence of FM has both
clinical and economic relevance. Recognition of FM may
not always be straightforward because FM symptoms may
be part of or overlap with other diseases or syndromes.
Using the original 1990 American College of Rheuma-
tology (ACR) criteria (5), Wolfe et al estimated that the
prevalence of FM in the US general population is 2%
(3.4% in women versus 0.5% in men) (6). Similarly, White
et al (7), reporting on the London Fibromyalgia Epidemi-
ology Study in Ontario, Canada, estimated the prevalence
of FM at 3.3% (4.9% in women versus 1.6% in men), and
Branco et al (8) reported on a multinational study of the
prevalence of FM in 5 European countries, estimating it at
4.7%. A separate study using a method similar to that of
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the ACR diagnostic criteria estimated the prevalence in
Germany at 3.8%, with similar rates in men and women
(9). These differing estimates may reﬂect differences in
study populations, study designs, and measurements.
In 2010, the ACR published diagnostic criteria for FM
that encompass the chronic widespread pain, fatigue, un-
refreshing sleep, cognition, and somatic symptoms consid-
ered the hallmarks of this condition (10). These criteria
were later modiﬁed to allow their use in epidemiologic
and survey studies, without the requirement for an exam-
iner to perform a tender point examination (11). The mod-
iﬁcation involved asking patients to report both pain and
tenderness for the widespread pain index, in comparison
to the ACR 2010 diagnostic criteria that only asked health
care providers to determine areas of pain. Additionally, 3
representative items substituted for the comprehensive list
of somatic symptoms that composed the ACR 2010 symp-
tom severity score: 1) the presence or absence of head-
aches, 2) pain or cramps in the lower abdomen, and 3) de-
pression in the past 6 months. Similar to the 2010 clinical
criteria for FM, the modiﬁed criteria included a wide-
spread pain index score of 7 and a symptom severity
score of 5. Alternatively, participants are deﬁned as hav-
ing FM if the widespread pain index is 3–6 or the symp-
tom severity score is 9. Additionally, symptoms must
have been present at a similar level for at least 3 months.
Routine use of these criteria in epidemiologic research
may improve comparability of FM prevalence in different
populations.
Our primary objective in this study was to estimate the
prevalence of FM in a deﬁned population in 2 different
ways. To accomplish this objective, we ﬁrst estimated the
prevalence of diagnosed FM in clinical practice in Olm-
sted County, Minnesota, using community medical re-
cords. We then surveyed a random sample of the popula-
tion of Olmsted County using the modiﬁed 2010 ACR
criteria to estimate the percentage of responders who ful-
ﬁlled the criteria.
PATIENTS AND METHODS
The study was approved by the Institutional Review
Boards of both Mayo Clinic and Olmsted Medical Center.
Patients were included in the study only if they were
residents of Olmsted County who had granted permission
for review of their medical records and had agreed to be
contacted for research.
Rochester Epidemiology Project (REP). Most health
care for residents of Olmsted County is delivered by 3
medical facilities and their afﬁliated hospitals: Mayo
Clinic, Olmsted Medical Center, and the Rochester Family
Medicine Clinic. Each institution uses a unit (or dossier)
medical record system, whereby data from an individual
(e.g., demographics, diagnoses, and billing records) are
assembled in one place and are made available for ap-
proved research studies under the umbrella of the REP
(12). The REP maintains an index of the diagnostic
codes obtained from all of the participating providers.
The REP diagnostic index includes diagnostic codes from
the International Classiﬁcation of Diseases, Ninth Revision
(ICD-9) and from the Hospital Adaptation of the Interna-
tional Classiﬁcation of Diseases (HICDA) for conditions
identiﬁed by physicians during ofﬁce visits or hospital
stays. This index can be searched to identify groups
of patients with a particular condition of interest in the
Olmsted County population. The REP staff then facili-
tates access to the medical records at each institution,
so that investigators can abstract details of medical care
directly from the medical charts of patients. Virtually
the entire Olmsted County population is captured by this
system (13).
Subjects and case ascertainment. Prevalence of diag-
nosed FM. To identify patients with diagnosed FM (i.e.,
an FM diagnosis documented in the medical record), we
used the REP diagnostic index and retrieved a list of all
Olmsted County residents ages 21 years who had re-
ceived a diagnosis using the HICDA code 07893-21-3 (FM)
or the ICD-9 code 729.1 (myalgia, myositis, ﬁbromyositis,
or FM) between January 1, 2005, and December 31, 2009.
Since these codes are not speciﬁc to FM and include
diagnoses such as myalgias, myositis, and ﬁbromyositis,
we reviewed the individual medical records of all of the
patients retrieved in this search to identify patients who
had an FM diagnosis documented by a health care pro-
vider in a clinical note in the medical record.
Prevalence of FM in the general population of Olmsted
County. We estimated the prevalence of FM in the Olm-
sted County population by mailing a survey that included
the modiﬁcation of the 2010 ACR criteria for FM (11). For
the purposes of this study, we refer to this survey as the
“FM research survey.”
Because the REP captures data on virtually the entire
Olmsted County, Minnesota, population, it serves as an
ideal, population-based sampling frame for survey studies
(13). We used the REP research infrastructure to identify
all residents of Olmsted County in 2010. We then used
the REP to identify a stratiﬁed random sample of 2,994
adults in Olmsted County and mailed the FM research
survey to them. We sampled approximately equal propor-
tions of men and women across the 3 age strata (21–39
years, 40–59 years, and 60 years). To maximize the re-
sponse rate, we sent a reminder postcard at 2 weeks (only
to nonrespondents), and at 4 weeks we sent a second
survey (only to nonrespondents). For survey respondents
who met FM survey criteria, we reviewed their medical
Signiﬁcance & Innovations
● This is the ﬁrst prevalence study in the US using
the 2010 ﬁbromyalgia (FM) research criteria.
● Prevalence in the same population was calculated
using 2 methods.
● Men who satisfy the 2010 FM research criteria are
unlikely to be diagnosed with FM.
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records to determine whether they had also received a
diagnosis of FM from a health care provider.
FM research survey in patients with a diagnosis of FM.
Patients with physician-diagnosed FM who were identi-
ﬁed through the medical record review were also mailed
the FM research survey. This step was taken to determine
the percentage of these patients who also met the FM
research survey criteria. To maximize the response rate,
we sent a reminder survey to this group at 4 weeks (only to
nonrespondents).
Statistical analysis. To estimate the prevalence of
diagnosed FM, we identiﬁed all adults (ages 21 years)
who were alive and residing in Olmsted County on De-
cember 31, 2009, who had a diagnosis of FM in their
medical record. An overall crude rate of prevalence was
estimated on the basis of the proportion of all prevalent
cases among the entire adult population in the county
(as enumerated using census ﬁgures), and likewise for age-
and sex-speciﬁc prevalence computed within those strata.
Age- and sex-adjusted prevalence was then computed us-
ing direct standardization to the total US population for
the year 2000 (14). Ninety-ﬁve percent conﬁdence inter-
vals (95% CIs) were estimated, assuming that the prevalent
cases followed a binomial distribution.
In our second approach, we surveyed a random sample
of the county for FM symptoms using the FM research
survey. We then estimated the prevalence of survey-based
FM to be the proportion of all respondents who met FM
survey criteria. Because of the method of sampling (age-
and sex-stratiﬁed random sampling), the sample from
which this prevalence estimate was derived differs from
the population of Olmsted County adults that served as the
denominator in the ﬁrst approach. However, when the
same direct adjustment approach (as described above) was
applied, the resulting age- and sex-adjusted prevalence of
survey-based FM could be more directly compared to the
prevalence of clinically-diagnosed FM.
In addition, descriptive statistics were used to sum-
marize demographic, comorbid, and clinical characteris-
tics of the diagnosed and survey-based prevalence cases.
For a formal comparison of characteristics between these 2
Figure 1. Flow chart of participant identiﬁcation by methodology. FM  ﬁbromyalgia.
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groups, the 2-sample t-test or the chi-square test was
used, as appropriate. Poisson regression analysis was
used to formally test for age and sex trends in prevalence.
P values less than 0.05 were considered statistically sig-
niﬁcant.
RESULTS
Prevalence of diagnosed FM. Using the REP medical
index, we identiﬁed 3,410 patients with the HICDA code
07893-21-3 or the ICD-9 code 729.1 for the period between
January 1, 2005, and December 31, 2009. Of these 3,410
patients, 86 (2.5%) denied consent for medical record
review and 160 (4.7%) were not residents of Olmsted
County in 2009 (Figure 1). We reviewed the medical re-
cords of the remaining 3,164 patients, and identiﬁed 1,115
patients with an FM diagnosis documented in the medical
record by a health care provider. The age- and sex-adjusted
prevalence of diagnosed FM in Olmsted County was esti-
mated at 1.1% (95% CI 1.07–1.20%) (Table 1). Prevalence
estimates increased with age (0.42% for the age group
21–39 years, 1.42% for the age group 40–59 years, and
1.91% for the age group 60 years; P  0.001). The age-
adjusted prevalence rate in women was signiﬁcantly
higher than that in men (2.00% versus 0.15%; P  0.001
for each). The 95% CIs for these estimates are shown in
Table 1.
Prevalence of FM in the general population of Olmsted
County. Overall, 830 (27.6%) of the stratiﬁed random
sample of 2,994 Olmsted County residents responded to
the survey (Table 1). Of the 830 respondents, 44 (5.3%)
met the FM research survey criteria (Figure 1). On the basis
of this sample and method, the age- and sex-adjusted prev-
alence of FM in the general population of Olmsted County
was estimated to be 6.4% (Table 1). Although not statisti-
cally signiﬁcant, the prevalence of FM tended to be higher
in women than in men (7.71% versus 4.88%; P  0.08,
adjusted for age). There was also a borderline association
of higher prevalence in younger ages (8.45% in the age
group 21–39 years, 6.02% in the age group 40–59 years,
and 3.79% in the age group 60 years; P  0.05, adjusted
for sex), which is in contrast to the trend of increasing
prevalence of diagnosed FM with older age. The 95% CIs
for these estimates are shown in Table 1.
Comparison of responders who met the FM research
survey criteria in either group. Overall, 492 (44%) of the
1,115 patients with diagnosed FM responded to the mailed
FM research survey. Of these, 370 (75%) met the FM
research survey criteria (Table 2). Compared to the re-
sponders to the survey from the general population of
Olmsted County who met the FM research survey criteria,
the group with diagnosed FM who also met the FM re-
search survey criteria included signiﬁcantly fewer men
(6% versus 34%; P  0.001), and on average had higher
symptom severity scores (mean  SD score 11.8  3.8
Table 1. Prevalence by age and sex of diagnosed and reported FM in residents of Olmsted County, Minnesota*
Type of rate
Diagnosed FM in Olmsted County† Survey-based FM from random sample‡
Count Prevalence, % 95% CI Count Denominator Prevalence, % 95% CI
Age 21–39 years
Unadjusted (women) 151 0.74 0.62–0.86 9 84 10.71 4.90–20.34
Unadjusted (men) 17 0.09 0.05–0.14 3 58 5.17 1.07–15.12
Unadjusted (total) 168 0.42 0.35–0.48 12 142§ 8.45 4.37–14.76
Age 40–59 years
Unadjusted (women) 519 2.62 2.40–2.85 8 143 5.59 2.42–11.02
Unadjusted (men) 28 0.15 0.10–0.22 8 123 6.50 2.81–12.82
Unadjusted (total) 547 1.42 1.30–1.54 16 266¶ 6.02 3.44–9.77
Age 60–110 years
Unadjusted (women) 376 3.14 2.83–3.48 12 199 6.03 3.12–10.53
Unadjusted (men) 24 0.27 0.17–0.40 4 223 1.79 0.49–4.59
Unadjusted (total) 400 1.91 1.73–2.11 16 422# 3.79 2.17–6.16
All ages
Unadjusted (women) 1,046 2.00 1.88–2.12 29 426 6.81 4.56–9.78
Unadjusted (men) 69 0.14 0.11–0.18 15 404 3.71 2.08–6.12
Unadjusted (total) 1,115 1.12 1.05–1.18 44 830** 5.30 3.85–7.12
Age adjusted (women) 1,046 2.00 1.88–2.12 29 426 7.71 4.65–10.77
Age adjusted (men) 69 0.15 0.12–0.19 15 404 4.88 2.08–7.69
Age and sex adjusted (total) 1,115 1.13 1.07–1.20 44 830 6.36 4.28–8.44
* FM  ﬁbromyalgia; 95% CI  95% conﬁdence interval.
† Data from the Rochester Epidemiology Project for patients with a clinical diagnosis of FM in the medical record.
‡ Data from responses to the survey conducted in 2011.
§ Response rate of 16.2% among 877 subjects ages 21–39 years.
¶ Response rate of 25.7% among 1,036 subjects ages 40–59 years.
# Response rate of 39% among 1,081 subjects ages 60 years.
** Response rate of 27.7% among 2,994 subjects (full sample).
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versus 8.6  3.6; P  0.001) (Table 2). Additionally, only
12 (27.2%) of the 44 responders to the survey from the
general population of Olmsted County who met the FM
research survey criteria had an FM diagnosis from a health
care provider.
DISCUSSION
The age- and sex-adjusted prevalence of diagnosed FM in
Olmsted County (the rate at which FM is being diagnosed
in the community of Olmsted County) was 1.1%. Since
this study is the ﬁrst to examine the prevalence of diag-
nosed FM in the county, it is not possible to directly
compare this estimate with other prevalence estimates.
The age- and sex-adjusted prevalence of FM as assessed by
the FM research survey was 6.4%. Since, to the best of our
knowledge, this is the ﬁrst study to estimate the preva-
lence of FM as assessed by the FM research survey, it is not
possible to directly compare this estimate with other prev-
alence estimates. These are 2 distinct prevalence rates
utilizing 2 different methodologies (i.e., the rate at which
FM is being diagnosed in the community and the percent-
age of people in the community who self-report symptoms
that constitute criteria for the FM research survey). These
prevalence rates can only be interpreted within the context
of the methodology utilized.
Although the rate of diagnosis of FM in the community
is 1.1%, the actual prevalence of the syndrome in the
community may be higher. Possible reasons for under-
estimation could include the lack of systematic assessment
of FM in the clinic, lack of consideration of the diagnosis
of FM, physician beliefs regarding the diagnosis of FM,
or if the focus of the medical visit was another medical
problem. The estimate, however, is very important, since
this is the ﬁrst study to assess the actual diagnosed prev-
alence. One could importantly conclude that FM is not
being diagnosed as often as might have been the case had
there been systematic assessment.
Similarly, although the FM research survey criteria are
modiﬁed from the FM clinical criteria, they are not equiv-
alent. The assessment of eligibility of 2010 FM clinical
criteria occurs in a clinical setting during a detailed, face-
to-face assessment. In contrast to this, the FM research
survey is designed to be an instrument to self-report (not
self-diagnose) symptoms of FM and is validated for epi-
demiologic studies to estimate the number of people who
endorse the symptom constellation of FM. Therefore,
the FM research survey criteria can only be interpreted
as meeting “survey criteria” and not meeting “clinical
criteria.”
Additionally, the prevalence of FM, as assessed by the
FM research survey criteria, unexpectedly showed a neg-
ative association with age. This is unexpected, since in-
creasing prevalence of FM with age is a consistent ﬁnding
in previous reports (7,15). The most likely explanation for
this is participation bias and, given that the lower response
rates we observed corresponded to the younger ages, it
seems plausible that subjects with higher disease activity
were overrepresented among younger participants.
Compared to men, the age-adjusted prevalence rates
of FM in women were signiﬁcantly higher for both the
survey-based estimates and the clinical diagnosis esti-
mates. In women, the prevalence of survey-based FM was
nearly 3-fold higher than the prevalence of clinically di-
agnosed FM. In men, the difference was even greater, with
the prevalence of survey-based FM 20-fold higher than the
prevalence of clinically diagnosed FM. These data high-
light a key difference between the 1990 criteria (which
require the presence of 11 or more tender points) and the
2010 criteria. Women innately have many more tender
Table 2. Comparison of clinically diagnosed and Olmsted County population who met
FM research survey criteria*
Diagnosed FM cases
who met survey
criteria
(n  370)†
Olmsted County
population who met
FM survey criteria
(n  44) P
Age, mean  SD years 55.7  12.7 54.9  17.6 0.69
Sex, no. (%)  0.001
Male 21 (6) 15 (34)
Female 349 (94) 29 (66)
Responders with survey-based FM
FM score, mean  SD 20.2  4.8 16.7  4.1  0.001
Symptom severity score, mean  SD 11.8  3.8 8.6  3.6  0.001
Widespread pain score, mean  SD 8.4  2.0 8.0  2.0 0.23
Fatigue‡ 336/370 (91) 40/44 (91) 0.98
Trouble thinking‡ 231/370 (62) 24/44 (55) 0.31
Waking up tired‡ 324/369 (88) 37/44 (84) 0.48
Pain/cramps 251/367 (68) 27/41 (66) 0.74
Depression 254/366 (69) 26/43 (60) 0.23
Headache 312/365 (85) 33/42 (79) 0.24
* Values are the number/total (percentage) unless otherwise indicated. FM  ﬁbromyalgia.
† 370 diagnosed FM cases (75%) who met the FM survey criteria based on the subset of 792 responders.
‡ Moderate to severe.
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points than men (16), and therefore it is possible that even
if a woman and a man have the same exact symptom
proﬁle suggesting FM, the man is much less likely to meet
the 1990 criteria because he is much less likely than the
comparable woman to also have 11 tender points. Another
explanation for the sex differences in our study is that men
in Olmsted County tend to visit medical providers less
frequently than women do (12). Alternatively, health care
providers may be less likely to diagnose FM in men than in
women.
We also noted that the survey responders meeting the
FM research survey criteria in the general population had
symptom severity scores that were statistically less severe
than those of survey responders meeting the FM research
survey criteria who had also been diagnosed with FM. One
likely explanation for this ﬁnding could be that the illness
was not as distressing to this group or that they did not
seek care for reasons that remain unknown. Another likely
explanation of why the diagnosis of FM was not made by
health care providers in persons with lower scores may be
that they presented differently. However, a review of med-
ical records of the 44 subjects who met the criteria dem-
onstrated that 50% of them had at least one rheumatologic
disorder. Therefore, the explanation for our ﬁndings re-
quires further study.
A strength of our study is that we assessed the preva-
lence of FM in a deﬁned population using 2 different
methods. Our use of the REP data allowed us to identify
all FM diagnoses in the Olmsted County population
within a deﬁned period. The same population then served
as a sampling frame to assess the prevalence of FM using
the FM research survey. These 2 methods allowed us to
determine whether FM might be diagnosed less often than
it is actually prevalent in the Olmsted County population.
The differing methodologies also contribute to the differ-
ences observed. Wolfe et al reported that the modiﬁed ACR
2010 criteria were satisﬁed by only 60% of the patients
with a prior diagnosis of FM (11).
Limitations of our study include the low participation
rate in the survey of the Olmsted County population over-
all (27.7%), with a very low rate (16.2%) in the 21–39-year
age category. Because of this low participation rate and the
unexpectedly high FM rate in this category, our estimates
of FM in the general population are likely biased. If per-
sons with FM were more likely to complete the survey,
then our prevalence estimates of FM would be inﬂated.
Based on the assumption that having FM is associated
with increased comorbidity, we tested but found no sig-
niﬁcant difference in Charlson Index scores between sur-
vey responders and nonresponders in the youngest age
group. However, in the overall sample, we found a signif-
icant interaction between age and the Charlson Index that
indicated healthy older subjects were more likely to re-
spond and therefore overrepresented in the subgroup of
participants. Sex could also have accounted for bias in the
prevalence estimates, given its association with both sur-
vey FM and participation.
Another limitation of our study is that we were review-
ing medical records already in existence. Since this was
a medical record review, we were limited to the informa-
tion that was previously recorded at the time of a clinical
encounter. A physician reviewed all of the medical re-
cords for the presence of chronic widespread pain and
tender points. However, the exact number of tender points
was not always speciﬁed.
The age- and sex-adjusted prevalence of diagnosed FM
in Olmsted County was 1.1%, whereas the prevalence of
FM in Olmsted County by the survey method was 6.4%,
which is higher than most previous estimates. Our study
results suggest that persons (especially men) who satisfy
FM research criteria are unlikely to be diagnosed with FM.
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